

CITATION REPORT

List of articles citing

An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

DOI: 10.1097/ftd.ob013e318189596d
Therapeutic Drug Monitoring, 2008, 30, 662-9.

Source: <https://exaly.com/paper-pdf/45037433/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
103	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. 2009 , 64, 874-5		9
102	Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. 2009 , 7, 620-5		31
101	Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations. 2009 , 64, 875-7		3
100	Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. 2009 , 61, 470-5		22
99	A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. 2009 , 877, 3072-82		43
98	Determination of HIV drugs in biological matrices: a review. 2009 , 647, 1-13		17
97	Saquinavir, the pioneer antiretroviral protease inhibitor. 2009 , 5, 1313-22		23
96	A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. 2009 , 79, 1372-8		40
95	High-Performance Liquid Chromatography Methods to Simultaneous Determination of Anti-Retroviral Drugs in Biological Matrices. 2009 , 39, 108-125		9
94	A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92 ^{3,2}		19
93	Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?. 2010 , 24, 1078-9		19
92	Targeted anal cancer screening in HIV-infected patients: prevalence of screening indicators. 2010 , 24, 1086-1087		2
91	First evidence of a HIV-1 M/O recombinant form circulating outside Cameroon. 2010 , 24, 1079-82		18
90	<i>Pseudomonas</i> fingernail infection successfully treated with topical nadifloxacin in HIV-positive patients: report of two cases. 2010 , 24, 1087-8		11
89	Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. 2010 , 24, 1083-4		18
88	The fidelity of decision-making: the Achilles heel for the successful implementation of prevention modalities for HIV. 2010 , 24, 1077-8		1
87	A rare case of severe myopathy associated with etravirine use. 2010 , 24, 1088-90		5

86	High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma. 2010 , 33, 1426-9	11
85	Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection. 2010 , 878, 456-60	10
84	An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. 2010 , 53, 113-8	8
83	Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. 2010 , 878, 1455-65	100
82	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 2010 , 52, 774-80	62
81	Raltegravir penetration in seminal plasma of healthy volunteers. 2010 , 54, 2744-5	13
80	Is peritoneal fluid a sanctuary site for HIV?. 2010 , 65, 2052-3	1
79	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. 2010 , 54, 5242-50	63
78	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. 2010 , 24, 931-2	11
77	Successful initiation of an anal cancer screening and treatment program at a New York City HIV clinic. 2010 , 24, 1085-6; author reply 1086-7	3
76	Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART. 2011 , 16, 797-803	7
75	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 2011 , 16, 499-504	9
74	[Evidence-based therapeutic drug monitoring for indinavir]. 2011 , 66, 239-46	1
73	Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. 2011 , 10, 141	11
72	Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. 2011 , 46, 202-8	13
71	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 2011 , 54, 779-88	55
70	Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. 2011 , 66, 224-5	15
69	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. 2011 , 66, 1932-4	7

68	Intrapatent and interpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5	3.2	29
67	Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Virus Infection. 2012 , 373-396		
66	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. 2012 , 67, 2236-42		16
65	Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. 2012 , 10, 162-4		20
64	Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS. 2012 , 885-886, 138-49		27
63	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 2012 , 59, 109-16		53
62	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. 2012 , 74, 134-40		29
61	Efavirenz dose reduction in HIV-infected patients. 2012 , 13, 252-3		8
60	Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 2012 , 40, 69-75		5
59	Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. 2013 , 65, 800-5		5
58	Stability-indicating HPLC method for the determination of darunavir ethanolate. 2013 , 51, 471-6		17
57	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. 2013 , 936, 42-7		30
56	A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 2013 , 78-79, 217-23		21
55	Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 853-8	3.2	10
54	Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 258-63	3.2	9
53	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. 2013 , 68, 1686-8		10
52	Rare case of rilpivirine-induced severe allergic hepatitis. 2013 , 68, 484-6		7
51	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 2013 , 68, 907-10		18

50	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 2013 , 68, 482-4	3
49	Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients. 2013 , 27, 315-6	
48	A maintenance dose of atazanavir/ritonavir 200/100 mg once daily is effective in virologically suppressed HIV-1-infected patients. 2013 , 63, e81-2	6
47	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 2014 , 15, 1281-6	6
46	Determination of intracellular darunavir by liquid chromatography coupled with fluorescence detection. 2014 , 52, 1021-5	6
45	Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose. 2014 , 30, 835-6	3
44	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. 2014 , 94, 65-70	8
43	Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. 2014 , 58, 4042-7	12
42	Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. 2014 , 69, 1760-6	5
41	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 2014 , 69, 1436-9	4
40	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 2014 , 69, 241-5	24
39	Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 2014 , 88, 66-70	35
38	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 2014 , 69, 3061-6	34
37	Interpatient variability of darunavir concentrations in plasma during long-term antiretroviral monotherapy. 2014 , 13, 10-13	2
36	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. 2014 , 108, 44-7	6
35	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 695-6	3,2 2
34	Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases. 2015 , 17, 147-53	4
33	Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients. 2015 , 68, e59-61	2

32	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. 2015 , 45, 545-9		4
31	Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. 2015 , 7, 5822		11
30	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. 2015 , 1001, 35-40		12
29	Metabolic Abnormalities in HIV-Infected Populations without or with Antiretroviral Therapy (ART). 2015 , 17-49		
28	Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode. 2015 , 5, 101-109		2
27	Class-specific relative genetic contribution for key antiretroviral drugs. 2015 , 70, 3074-9		10
26	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). 2015 , 70, 3096-9		14
25	UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. 2015 , 115, 443-9		9
24	Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 407-13	3.2	16
23	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. 2017 , 72, 812-815		6
22	Efavirenz pharmacogenetics in a cohort of Italian patients. 2016 , 47, 117-23		21
21	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. 2016 , 73, 750-4		1
20	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. 2017 , 87, 30-36		5
19	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. 2017 , 138, 223-230		34
18	Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. 2017 , 9, 6302-6314		28
17	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. 2018 , 73, 160-164		1
16	UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. 2018 , 1073, 183-190		29
15	Clinical and genetic determinants of nevirapine plasma trough concentration. 2018 , 6, 2050312118780861		7

14	Tuning HIV drug release from a nanogel-based in situ forming implant by changing nanogel size. 2019 , 7, 373-383	14
13	Solid-phase extraction combined with dispersive liquid-liquid microextraction/HPLC-UV as a sensitive and efficient method for extraction, pre-concentration and simultaneous determination of antiretroviral drugs nevirapine, efavirenz and nelfinavir in pharmaceutical formulations and biological samples. 2019 , 166, 95-104	7
12	Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. 2020 , 33, 106445	1
11	Data on the stability of darunavir/cobicistat suspension after tablet manipulation. 2020 , 30, 105552	6
10	Darunavir: A comprehensive profile. 2021 , 46, 1-50	2
9	Multiresponse Optimization of HPLC Method: Simultaneous Estimation of Protease Inhibitors and NNRTI in Human Plasma. 2021 ,	
8	Analytical Method Development and Validation of Etravirine by RP-UFLC. 2021 , 3537-3542	
7	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. 2021 , 9,	1
6	Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review. 2019 , 14, 16-57	2
5	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. 2020 , 14,	2
4	Spectrophotometric Determination of Etravirine in Bulk and Pharmaceutical Formulations. 2014 , 05, 77-82	3
3	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. <i>Nutrients</i> , 2021 , 13,	6.7 1
2	Analytical Techniques for the Analysis of Lopinavir and Ritonavir in Pharmaceutical Dosage Form and Biological Matrices: A Review. <i>Current Pharmaceutical Analysis</i> , 2022 , 18, 380-414	0.6
1	Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study.	0